Martin Currie Ltd. Has $26.93 Million Stake in Eli Lilly and Company $LLY

Martin Currie Ltd. reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 34,544 shares of the company's stock after selling 298 shares during the period. Eli Lilly and Company accounts for about 1.0% of Martin Currie Ltd.'s portfolio, making the stock its 29th largest holding. Martin Currie Ltd.'s holdings in Eli Lilly and Company were worth $26,928,000 as of its most recent SEC filing.

• A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves

A number of other large investors also recently modified their holdings of LLY. Braun Bostich & Associates Inc. grew its stake in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company's stock valued at $411,000 after buying an additional 13 shares in the last quarter. Rise Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock valued at $1,533,000 after purchasing an additional 13 shares during the period. New Insight Wealth Advisors grew its holdings in Eli Lilly and Company by 3.4% during the second quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock worth $307,000 after purchasing an additional 13 shares during the period. Finally, Dash Acquisitions Inc. increased its position in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock worth $387,000 after buying an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.6%

Shares of Eli Lilly and Company stock opened at $1,042.86 on Friday. The firm has a 50-day moving average of $849.83 and a 200-day moving average of $786.02. The stock has a market cap of $985.90 billion, a PE ratio of 68.16, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,057.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company's payout ratio is presently 29.35%.

Analysts Set New Price Targets

• Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

Several research analysts have recently commented on the company. Weiss Ratings reiterated a "hold (c+)" rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Monday, November 10th. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an "overweight" rating in a report on Thursday, November 13th. Scotiabank assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a "sector outperform" rating and a $1,165.00 target price for the company. Finally, Berenberg Bank reiterated a "hold" rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $1,027.95.

View Our Latest Stock Report on LLY

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

• Five stocks we like better than Eli Lilly and Company
• TSX Venture Exchange (Formerly Canadian Venture Exchange)
• Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
• How to Buy Cheap Stocks Step by Step
• Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
• How to Effectively Use the MarketBeat Ratings Screener
• Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here